Mavacamten Favorably Impacts Cardiac Structure in Obstructive Hypertrophic Cardiomyopathy: EXPLORER-HCM Cardiac Magnetic Resonance Substudy Analysis

Affiliations

• ¹ Department of Internal Medicine, Division of Cardiovascular Medicine, University of Michigan Medical School, Ann Arbor (S.S.).
• ² Department of Cardiology, Cardiovascular MR and CT unit (UNICA), Hospital da Luz, Lisbon, Portugal (N.C.).
• ³ Mayo Clinic, Jacksonville, FL (M.Y.).
• ⁴ Charité Medical University Berlin, ECRC and Department of Cardiology, HELIOS Klinik Berlin-Buch, Clinic for Cardiology and Nephrology, DZHK partnersite Berlin, Germany (J.S-M.).
• ⁵ MyoKardia, Brisbane, CA (W.L., V.F., A.J.S.).
• ⁶ Cardiovascular Division, Department of Medicine (R.Y.K., M.J-H.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
• ⁷ Center for Hypertrophic Cardiomyopathy, Knight Cardiovascular Institute, Oregon Health & Science University, Portland (A.M.).
• ⁸ Center for Inherited Cardiac Disease, Division of Cardiovascular Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia (A.O.).
• ⁹ Department of Cardiovascular Medicine (N.K.L.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
• ¹⁰ Cardiovascular Division, Department of Medicine, University of Virginia Health System, Charlottesville (C.M.K.).
• ¹¹ Hypertrophic Cardiomyopathy Program, NYU Langone Health, New York (M.S.).
• ¹² Department of Cardiology and Pulmonology, University Medical Center Göttingen, Germany (T.S.).
• ¹³ Duke Cardiology, Duke Health Center at Southpoint, Durham, NC (A.W.).
• ¹⁴ Department of Internal Medicine III, Institute for Cardiomyopathies, University of Heidelberg, Germany (F.S.-H., B.M.).
• ¹⁵ Department of Cardiology, Tel Aviv Medical Center, affiliated to Sackler School of Medicine, Tel Aviv University, Israel (O.H.).
• ¹⁶ Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, CT (D.J.).